MedPath

Effects of Diabetan and Saliva officinalis L tablets on blood glucose levels of patients with type 2 DM.

Phase 2
Conditions
Diabetes Melitus (DM).
Diabetes Melitus
E10, E11,
Registration Number
IRCT201011112696N2
Lead Sponsor
Gol Daru Co.
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
All
Target Recruitment
80
Inclusion Criteria

Inclusion Criteria: 1-Having type 2 diabetes based on internal criteria with FBS=126 or more and blood glucose 200 or more in daytime. 2- HbA1C more than 7% and less than 9% 3-Not having side effects of DM 4-Non- insulin dependent 5-Willing to participate in the trial 6-Not having a crucial illness 7- psychologically normal 8- Not using any other drugs for other diseases. Excluding Criteria: 1- Hyperglycemia with HbA1C more than 250 2-2hpp more than 9% and less than 7% 3-Pragnancy and lactation 4- Using insulin 5- Not willing to enter the trial 6- Having side effects of DM 7- Cardiovascular, hepatic, renal and other major systemic diseases 8- psychologically abnormal 9- Using drugs for other illnesses 10- Type 1 DM 11- Age less than 30 years

Exclusion Criteria

Not provided

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
HbA1C. Timepoint: At the beginning and at the end of trial (in 3 months. Method of measurement: Laboratory mg/ dl.;Lipid profile. Timepoint: At the beginning and end of the trial (in 3 months). Method of measurement: mg/dl through lab methods.;Liver and kidney parameters. Timepoint: At the beginning and end of the trial (in 3 months). Method of measurement: mg/dl through lab methods.;FBS and HbA1C. Timepoint: at the beginning of trial and every 2 weeks. Method of measurement: mg/dl.
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath